Evidence map›Paper›PMID 34798027›Full record

ArticleThe Lancet. Global health2021

Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae.

Nicolas A Menzies, Matthew Quaife, Brian W Allwood, Anthony L Byrne, Anna K Coussens, Anthony D Harries, Florian M Marx, Jamilah Meghji, Debora Pedrazzoli, Joshua A Salomon and 5 more

Erratum issued Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in The Lancet. Global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06127641 (Rehabilitation of People With Post-tuberculosis Lung Disease), which is not on this map. Cited by 157 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
157citing papers in PubMed, 2 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06127641 narecruitingnot on this mapstarted 2023, after this paper: background citation

Rehabilitation of People With Post-tuberculosis Lung Disease

TypeinterventionalSponsorCentro Universitário Augusto MottaRan2023 to 2027Enrolled40ConditionsPulmonary TuberculosisArmsStandard care plus pulmonary rehabilitation, Standard Care
3 · Its place in the literature

Who cites it

157 citing papers in PubMed, 2 syntheses or guidelines pooled it, 206 citations in OpenAlex.

  1. Pooled it
  2. The prevalence of pulmonary hypertension in post-tuberculosis and active tuberculosis populations: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2024
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Post-tuberculosis lung disease in treated extra-pulmonary tuberculosis.American journal of respiratory and critical care medicine · 2026
    Article
  10. Cost-effectiveness of community tuberculosis screening in South Africa.American journal of respiratory and critical care medicine · 2026
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

97 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 7 countries.

Nicolas A MenziesDepartment of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA; Center for Health Decision Science, Harvard TH Chan School of Public Health, Boston, MA, USA. Electronic address: nmenzies@hsph.harvard.edu.
Matthew QuaifeTB Modelling Group, TB Centre, London School of Hygiene & Tropical Medicine, London, UK; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Brian W AllwoodDivision of Pulmonology, Department of Medicine, Stellenbosch University, Stellenbosch, South Africa.
Anthony L ByrneHeart Lung Clinic, St Vincent's Hospital, Sydney, NSW, Australia; Faculty of Medicine, St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia; Socios En Salud Sucursal Peru, Partners In Health, Lima, Peru.
Anna K CoussensInfectious Diseases and Immune Defence Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory WC, South Africa; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
Anthony D HarriesFaculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; International Union Against Tuberculosis and Lung Disease, Paris, France.
Florian M MarxDSI-NRF South African Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Jamilah MeghjiDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Debora PedrazzoliTB Modelling Group, TB Centre, London School of Hygiene & Tropical Medicine, London, UK; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Joshua A SalomonDepartment of Medicine, Stanford University, Palo Alto CA, USA.
Sedona SweeneyFaculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.
Sanne C van KampenDepartment of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands.
Robert S WallisThe Aurum Institute, Parktown, Johannesburg, South Africa; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Medicine, Rutgers University, Newark, NJ, USA.
Rein M G J HoubenTB Modelling Group, TB Centre, London School of Hygiene & Tropical Medicine, London, UK; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Ted CohenDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
London School of Hygiene & Tropical Medicine · GBStellenbosch University · ZAAurum Institute · ZAEsSALUD · PEFaculty of Public Health · GBHarvard Global Health Institute · USInternational Union Against Tuberculosis and Lung Disease · FRLeiden University Medical Center · NLLiverpool School of Tropical Medicine · GBStanford University · USWellcome Centre for Infectious Diseases Research in Africa · ZAYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Optimal targeting for individual and population-level TB preventionR01AI146555 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI MENZIES, NICOLAS A · 2020 to 2024
$2.5M
Gates Foundation INV-001754Medical Research Council MR/S02042X/1NCATS NIH HHS UL1 TR001863NIAID NIH HHS R01 AI146555
6 · The paper itself

Abstract

backgroundMany individuals who survive tuberculosis disease face ongoing disability and elevated mortality risks. However, the impact of post-tuberculosis sequelae is generally omitted from policy analyses and disease burden estimates. We therefore estimated the global burden of tuberculosis, inclusive of post-tuberculosis morbidity and mortality.

methodsWe constructed a hypothetical cohort of individuals developing tuberculosis in 2019, including pulmonary and extrapulmonary disease. We simulated lifetime health outcomes for this cohort, stratified by country, age, sex, HIV status, and treatment status. We used disability-adjusted life-years (DALYs) to summarise fatal and non-fatal health losses attributable to tuberculosis, during the disease episode and afterwards. We estimated post-tuberculosis mortality and morbidity based on the decreased lung function caused by pulmonary tuberculosis disease.

findingsGlobally, we estimated 122 (95% uncertainty interval [UI] 98-151) million DALYs due to incident tuberculosis disease in 2019, with 58 (38-83) million DALYs attributed to post-tuberculosis sequelae, representing 47% (95% UI 37-57) of the total burden estimate. The increase in burden from post-tuberculosis varied substantially across countries and regions, driven largely by differences in estimated case fatality for the disease episode. We estimated 12·1 DALYs (95% UI 10·0-14·9) per incident tuberculosis case, of which 6·3 DALYs (5·6-7·0) were from the disease episode and 5·8 DALYs (3·8-8·3) were from post-tuberculosis. Per-case post-tuberculosis burden estimates were greater for younger individuals, and in countries with high incidence rates. The burden of post-tuberculosis was spread over the remaining lifetime of tuberculosis survivors, with almost a third of total DALYs (28%, 95% UI 23-34) accruing 15 or more years after incident tuberculosis.

interpretationPost-tuberculosis sequelae add substantially to the overall disease burden caused by tuberculosis. This hitherto unquantified burden has been omitted from most previous policy analyses. Future policy analyses and burden estimates should take better account of post-tuberculosis, to avoid the potential misallocation of funding, political attention, and research effort resulting from continued neglect of this issue.

fundingNational Institutes of Health.

Indexed as

Cost of IllnessQuality-Adjusted Life YearsFemaleGlobal Burden of DiseaseGlobal HealthHumansMalePersons with DisabilitiesRisk FactorsSurvivorsTuberculosis

Identifiers

PMID34798027
PMCPMC8609280
OpenAlexW3214641779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.